O Orexo AB
O
Abrir
20.9 8.52
Visão Geral
Variação de preço das ações
24h
Mín
19.24
Máximo
20.95
Rendimento | 41M -75M |
|---|---|
Vendas | 1.7M 5M |
EPS | -3.812 |
Margem de lucro | -1,500 |
Funcionários | 65 |
EBITDA | 206M -66M |
Próximos Ganhos | 16 de jul. de 2026 |
|---|
Capitalização de Mercado | -35M 665M |
|---|---|
Abertura anterior | 12.38 |
Fecho anterior | 20.9 |
Orexo AB Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
